Esophageal Squamous Cell Carcinoma
Conditions
Keywords
Chemoradiation, Immunotherapy, Advanced esophageal cancer, Low PD-L1 expression, Progression-free survival
Brief summary
This study is a multicentre, randomised, parallel-controlled, open-label, 3 phase clinical trial. The subjects were untreated, unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma with low PD-L1 expression. Patients were randomly assigned to receive chemoradiation or chemotherapy in combination with Tislelizumab at a ratio of 1: 1. The primary endpoint was progression-free survival (PFS) in the intention-to-treat population. We hypothesized that in advanced esophageal squamous cell carcinoma patients with low PD-L1 expression, chemoradiation versus chemotherapy in combination with Tislelizumab will significantly improve PFS.
Interventions
Esophageal primary tumor: 39.6Gy/2.2Gy Bone metastasis: 30Gy/3Gy Lung, liver, brain metastases, metastatic lymph nodes: 45Gy/3Gy
DRUGTislelizumab
200 mg IV Q3W
DRUGCisplatin
During concurrent radiation therapy: 25 mg/m² IV QW During consolidation therapy: 75 mg/m² IV Q3W
DRUGNab paclitaxel
During concurrent radiation therapy: 75 mg/m² IV QW During consolidation therapy: 220 mg/m² IV Q3W
Sponsors
Renmin Hospital of Wuhan University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Subjects must have histologically confirmed squamous cell carcinoma of esophagus (per AJCC 8th edition). 2. Subjects must have unresectable advanced, recurrent or metastatic ESCC. 3. Subjects must not be amenable to curative approaches such as definitive chemoradiation and/or surgery. 4. PD-L1 expression (CPS) is less than 10. 5. No prior systemic anticancer therapy given as primary therapy for advanced or metastatic disease. 6. ECOG Performance Status of 0 or 1. 7. Subjects must have at least one measurable lesion by CT or MRI per RECIST 1.1 criteria; radiographic tumor assessment must be performed within 28 days prior to randomization. 8. Subjects must have adequate organ and bone marrow function.
Exclusion criteria
1. Presence of tumor cells in the brain or spinal cord which are symptomatic or require treatment. 2. Active known or suspected autoimmune disease. 3. Any serious or uncontrolled medical disorder or active infection. 4. Known history of positive test for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS). 5. Any positive test result for hepatitis B or C indicating acute or chronic infection and/or detectable virus. 6. Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression-Free Survival (PFS) | Approximately 40 months from date of the first participant randomization | PFS is defined as the time from the date of randomization to the date of first documentation of disease progression assessed by the investigator per RECIST v1.1 or death, whichever occurs first |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival (OS) | Approximately 40 months from date of the first participant randomization | Overall Survival (OS) is defined as the time between the date of randomization and the date of death. For participants without documentation of death, OS will be censored on the last date the subject was known to be alive. |
| Objective Response Rate (ORR) | Approximately 40 months from date of the first participant randomization | Objective response rate (ORR) is defined as the percentage of participants with a best overall response (BOR) of complete response (CR) or partial response (PR). Best overall response (BOR) is defined as the best response designation as determined by BICR, recorded between the date of randomization and the date of objectively documented progression (per RECIST 1.1) or the date of subsequent anti-cancer therapy (including tumor-directed radiotherapy and tumor-directed surgery), whichever occurs first. Partial response is defined as at least a 30% decrease in the sum of diameters of target lesions. Complete response is defined as the disappearance of all target lesions and the reduction of any pathological lymph nodes to \<10 mm. |
| Duration of Response (DOR) | Approximately 40 months from date of the first participant randomization | DOR is defined as the time from the first determination of an objective response until the first documentation of progression assessed by the investigator per RECIST v1.1 or death, whichever comes first |
| Number of participants experiencing Adverse Events (AEs) | Approximately 40 months from date of the first participant randomization | AEs are documented according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v4 |
Countries
China
Contacts
Primary ContactYongshun Chen, MD
Outcome results
None listed